Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts

NCT04358458 is registered in ClinicalTrials.gov with Genmab as lead sponsor.

NCT NCT04358458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04358458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts
Lead sponsor
Genmab
Phase
Phase 1/2
Overall status
Terminated
Start date
March 13, 2020
Completion date
July 28, 2023
Enrollment
46 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, diffuse large b-cell lymphoma, follicular lymphoma, high-grade b-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma, primary mediastinal large b-cell lymphoma, small lymphocytic lymphoma